In May 2021, Shanghai unveiled several support policies to promote the development of the biopharmaceutical industry.

The key policies include:

  Support for research and development (R&D) of innovative drugs:

For Category 1 chemical drugs, biologics and traditional Chinese medicines that have completed Phase I, II and III clinical trials in China and are produced by registered applicants in Shanghai, optimal support will be provided based on the different stages of clinical trials. The support funds will not exceed 40 percent of R&D investment, with a maximum amount of 5 million, 10 million and 30 million yuan, for different stages of clinical trials respectively. The cumulative amount for each unit is capped at 100 million yuan per year. The subsidies for Phase I and II clinical trials will be organized and approved by the Shanghai Municipal Science and Technology Commission, while the subsidies for Phase III clinical trials will be organized and approved by the Shanghai Municipal Commission of Economy and Informatization.

  Improve Customs clearance efficiency for R&D materials:

Establishing a joint assessment and supervision mechanism among multiple departments for the import of R&D materials, creating an information exchange and supervision platform covering the entire Customs clearance process, establishing a "white list" for biopharmaceutical pilot enterprises and materials in Shanghai, simplifying the pre-approval procedures for listed enterprises’ relevant materials, as well as facilitating Customs clearance for enterprises. Specific implementation is organized and approved by the Shanghai Municipal Commission of Commerce.

Source: fgw.sh.gov.cn